Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

pectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus' management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus', Alnylam's, and Isis' programs are described in additional detail in Alnylam's and Isis' annual reports on Form 10-K for the year ended December 31, 2010, and its most recent quarterly report on Form 10-Q.  Copies of these and other documents are available from Alnylam or Isis.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014 /PRNewswire/ ... acquired enzastaurin, a late-stage oncology drug, from Eli ... rights to develop, manufacture and commercialize enzastaurin globally, ... rights, data, and information. Lilly ... in Phase 2 and Phase 3 clinical trials ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
(Date:9/16/2014)... , Sept. 16, 2014   HemCon Medical ... of TriStar Wellness Solutions(R), Inc. (OTCQB: ... advanced medical products, announced today that the revenue ... by 39 percent, and microdispersed oxidized cellulose raw ... 2014.  Overall, TWSI expects third quarter revenues to ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 2HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 3HemCon Medical Technologies, Inc. Projects Strong Third Quarter Revenues 4
... April 26 Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... treatment of cancer, today announced that it will host a conference call ... Wednesday, May 5, 2010 , at 8:30 AM ET . , ... To participate in the conference ...
... , April 26 Cornerstone Therapeutics Inc. (Nasdaq: ... developing and commercializing significant products primarily for the respiratory and ... call at 8:00 AM ET on Tuesday, ... the quarter ended March 31, 2010 .  Management will ...
Cached Medicine Technology:Micromet to Report First Quarter 2010 Financial Results on May 5 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3
(Date:9/17/2014)... Tampa, FL (PRWEB) September 17, 2014 Tina ... ), is finishing up her chemotherapy but not her fight ... up for the Komen Florida Suncoast “Race for the Cure” ... “I registered for the Komen Race for the Cure because ... breast cancer,” Griffin said. , As part of her efforts, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Four ... eighth annual Wailea Tennis Fantasy Camp on ... Maui’s prestigious Wailea Tennis Club, with three-time grand slam ... returning to Wailea, Maui for her fifth year. , ... match play with Davenport, recently inducted into the International ...
(Date:9/17/2014)... September 17, 2014 A raucous childhood ... come together to form author Nancy Chovancek’s laughter-filled new ... is a collection of short stories that prove the ... fun. With a positive message of empowerment and resilience, ... is a proven author with two books under her ...
(Date:9/17/2014)... This September 18-20, 22 participating developmentally-disabled athletes ... three stage outdoor sporting event in non-profit World T.E.A.M. ... , Hosted at The Center for Discovery ... five participating teams coached by able-bodied athletes. For each ... provide expert guidance as well as technical assistance. Like ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Lee ... settlement industry, will be appearing on The Balancing Act® ... two September episodes. , The segment will premiere on ... on 'The Balancing Act® airing on Lifetime Television®' with ... of Asset Funding Corp. for over a decade and ...
Breaking Medicine News(10 mins):Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 2Health News:Four Seasons Resort Maui at Wailea Announces 8th Annual Wailea Tennis Fantasy Camp 3Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge New York Includes Disabled Athletes 3Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2
... Polyp Detection by Thirteen Percent, SAN DIEGO, ... in San Diego (DDW 2008), world-renowned gastroenterologist,Jerome D. ... which evaluated the efficacy of the Third Eye(TM) ... physicians to visualize,abnormalities in the colon., The ...
... near Mosul in 2003 , , WEDNESDAY, May 21 (HealthDay News) ... near Mosul, Iraq, in 2003 returned home with a debilitating ... , But doctors were only able to diagnose the condition, ... to reliably identify the problem, said the authors of a ...
... (Amex: QGP, QGP.WSA, QGP.WSB) ( http://www.QuantumMD.com ) ... plan. The Company,increased its employment base by 23% since ... ft. to 10,600 sq. ft., and has moved a,branch ... Doral (west,Miami), Florida., Susan Darby Guillama, Executive Vice ...
... MINNEAPOLIS, May 21 ACM today announced a ... development efforts on,providing next generation technology and services ... of healthcare today: commercial plans and,payers, and federal ... Development Gary Loeber has been,named EVP/General Manager for ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
... Calif., May 21 LUMEDX Corporation, a ... information systems,(CVIS), introduces software to manage data ... The Anticoagulation Module empowers clinicians,by making critical ... safety., For more information -- including ...
Cached Medicine News:Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Some Iraq War Vets Suffer Breathing Problems 2Health News:Some Iraq War Vets Suffer Breathing Problems 3Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2Health News:New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 2
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
... performance technologies - Quantum™ LEAP® balloon ... - unite in the Quantum™ Maverick® ... dilatation force balloon with exceptional deliverability. ... Maverick® shaft technology improves trackability and ...
... Libert Coronary Stent System ... of lesion access and ... a low crossing profile, ... catheter, the performance of ...
Medicine Products: